Patient-Reported Outcomes

TORPEdO Phase III Finds No One-Year Advantage for Proton Therapy Over IMRT in Oropharyngeal Cancer

Rigorous quality assurance produced comparable patient experience despite proton plans lowering dose to nearby tissues.